BDNF crosses the blood-brain barrier only in minimal amounts, making peripheral administration inadequate for treatment, as seen in a large clinical trial seeking to treat amyotrophic lateral sclerosis (ALS) [136]. The gene discussed is BDNF; the disease is amyotrophic lateral sclerosis.